127 related articles for article (PubMed ID: 9773801)
1. O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan.
Rosing H; van Zomeren DM; Doyle E; Bult A; Beijnen JH
Anticancer Drugs; 1998 Aug; 9(7):587-92. PubMed ID: 9773801
[TBL] [Abstract][Full Text] [Related]
2. Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan.
Rosing H; Herben VM; van Gortel-van Zomeren DM; Hop E; Kettenes-van den Bosch JJ; ten Bokkel Huinink WW; Beijnen JH
Cancer Chemother Pharmacol; 1997; 39(6):498-504. PubMed ID: 9118461
[TBL] [Abstract][Full Text] [Related]
3. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.
Zamboni WC; Gajjar AJ; Heideman RL; Beijnen JH; Rosing H; Houghton PJ; Stewart CF
Clin Cancer Res; 1998 Mar; 4(3):783-9. PubMed ID: 9533548
[TBL] [Abstract][Full Text] [Related]
4. Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods.
Rosing H; van Zomeren DM; Doyle E; ten Bokkel WW; Schellens JH; Bult A; Beijnen JH
J Chromatogr B Biomed Sci Appl; 1999 Apr; 727(1-2):191-203. PubMed ID: 10360438
[TBL] [Abstract][Full Text] [Related]
5. Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer.
Herben VM; ten Bokkel Huinink WW; Schot ME; Hudson I; Beijnen JH
Anticancer Drugs; 1998 Jun; 9(5):411-8. PubMed ID: 9660538
[TBL] [Abstract][Full Text] [Related]
6. [Topotecan: prospects for using it in combination therapy for ovarian carcinoma].
Scarfone G
Tumori; 1999; 85(6 Suppl 1):S12-5. PubMed ID: 10786195
[TBL] [Abstract][Full Text] [Related]
7. No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients.
Zackrisson AL; Malmström H; Peterson C
Eur J Clin Pharmacol; 2002 May; 58(2):103-8. PubMed ID: 12012141
[TBL] [Abstract][Full Text] [Related]
8. [Early results of topotecan therapy in patients with recurrent ovarian cancer].
Lehoczky O; Bagaméri A; Lehoczky G; Pulay T
Orv Hetil; 2002 Apr; 143(16):825-8. PubMed ID: 12053883
[TBL] [Abstract][Full Text] [Related]
9. [Single topotecan or in combination with other chemotherapeutic agents for 18 recurrent advanced ovarian cancer patients].
Li H; Liu L; Zhang W
Zhonghua Zhong Liu Za Zhi; 2001 Nov; 23(6):513-5. PubMed ID: 11859726
[TBL] [Abstract][Full Text] [Related]
10. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
Rose PG; Gordon NH; Fusco N; Fluellen L; Rodriguez M; Ingalls ST; Hoppel CL
Gynecol Oncol; 2000 Aug; 78(2):228-34. PubMed ID: 10926808
[TBL] [Abstract][Full Text] [Related]
11. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
12. Topotecan. A review of its potential in advanced ovarian cancer.
Brogden RN; Wiseman LR
Drugs; 1998 Oct; 56(4):709-23. PubMed ID: 9806112
[TBL] [Abstract][Full Text] [Related]
13. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer.
Clarke-Pearson DL; Van Le L; Iveson T; Whitney CW; Hanjani P; Kristensen G; Malfetano JH; Beckman RA; Ross GA; Lane SR; DeWitte MH; Fields SZ
J Clin Oncol; 2001 Oct; 19(19):3967-75. PubMed ID: 11579118
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
15. Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group.
Hochster H; Wadler S; Runowicz C; Liebes L; Cohen H; Wallach R; Sorich J; Taubes B; Speyer J
J Clin Oncol; 1999 Aug; 17(8):2553-61. PubMed ID: 10561322
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of 4'-modified analogs of doxorubicin. unique glucuronidation pathway for 4'-epidoxorubicin.
Weenen H; van Maanen JM; de Planque MM; McVie JG; Pinedo HM
Eur J Cancer Clin Oncol; 1984 Jul; 20(7):919-26. PubMed ID: 6589165
[TBL] [Abstract][Full Text] [Related]
17. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
Bookman MA; Malmström H; Bolis G; Gordon A; Lissoni A; Krebs JB; Fields SZ
J Clin Oncol; 1998 Oct; 16(10):3345-52. PubMed ID: 9779711
[TBL] [Abstract][Full Text] [Related]
18. Structures of (-)-epicatechin glucuronide identified from plasma and urine after oral ingestion of (-)-epicatechin: differences between human and rat.
Natsume M; Osakabe N; Oyama M; Sasaki M; Baba S; Nakamura Y; Osawa T; Terao J
Free Radic Biol Med; 2003 Apr; 34(7):840-9. PubMed ID: 12654472
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.
Garcia AA; Roman L; Muderspach L; O'meara A; Facio G; Edwards S; Burnett A
Cancer Invest; 2005; 23(8):665-70. PubMed ID: 16377584
[TBL] [Abstract][Full Text] [Related]
20. Topotecan in platinum-resistant epithelial ovarian cancer.
Karabulut B; Sezgin C; Terek MC; Uslu R; Sanli UA; Akman L; Ozsaran A; Dikmen Y; Goker E
Chemotherapy; 2005 Oct; 51(6):347-51. PubMed ID: 16227688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
